Financial Performance - The company's revenue for Q3 2023 was ¥89,151,674.77, a decrease of 49.42% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥3,657,889.40, down 93.40% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥116,850.09, a decline of 99.77% compared to the previous year[5] - Year-to-date revenue from January to September 2023 reached ¥746,127,863.80, an increase of 76.42% compared to the same period in 2022[12] - Total operating revenue for Q3 2023 reached CNY 746.13 million, a significant increase of 76.5% compared to CNY 422.92 million in the same period last year[26] - Net profit for Q3 2023 was CNY 313.19 million, up 186.5% from CNY 109.48 million in Q3 2022[27] - Basic and diluted earnings per share for Q3 2023 were both CNY 2.49, compared to CNY 0.87 in the previous year[28] Assets and Equity - The company's total assets as of September 30, 2023, were ¥1,861,731,324.57, reflecting a 1.00% increase from the end of the previous year[5] - The company's equity attributable to shareholders increased by 21.47% to ¥1,671,842,126.02 compared to the end of the previous year[5] - Total assets as of Q3 2023 amounted to CNY 1.86 billion, slightly up from CNY 1.84 billion at the end of the previous year[24] - The total equity attributable to shareholders of the parent company rose to CNY 1.67 billion, up from CNY 1.38 billion, marking an increase of 21.5%[24] Cash Flow and Investments - Cash received from sales and services for the first nine months of 2023 was approximately ¥514.41 million, an increase of 65.91% compared to ¥310.05 million in the same period of 2022[14] - Total cash inflow from investment activities reached ¥1,241,331,779.53, significantly up from ¥514,151,481.94 in the same period last year, marking an increase of 141.5%[31] - The net cash flow from investment activities was ¥25,532,994.27, recovering from a negative cash flow of -¥71,628,179.98 in Q3 2022[31] - The ending balance of cash and cash equivalents was ¥288,778,223.22, up from ¥226,440,815.64 at the end of Q3 2022, reflecting an increase of 27.5%[32] - The company received ¥1,235,000,000.00 from investment recoveries, a substantial increase from ¥510,000,000.00 in Q3 2022[31] Expenses and Liabilities - The company reported a significant increase in tax expenses, with a 267.70% rise in income tax expenses to ¥66,424,275.94 due to higher profits[12] - Cash paid for purchasing goods and services decreased by 39.50% to ¥82.59 million from ¥136.52 million, attributed to a reduction in raw material purchases[14] - Tax payments surged by 473.40% to ¥260.41 million from ¥45.41 million, mainly due to the implementation of tax deferral policies in the previous period[14] - Total liabilities decreased to CNY 189.89 million in Q3 2023 from CNY 466.89 million in the same period last year, indicating a reduction of 59.4%[24] Research and Development - Research and development expenses for the first nine months of 2023 were ¥34,942,697.26, an increase of 83.58% year-on-year, indicating a focus on R&D investment[12] - Research and development expenses for Q3 2023 were CNY 34.94 million, an increase of 83.3% from CNY 19.03 million in Q3 2022[26] Shareholder Information - The total number of common shareholders at the end of the reporting period was 26,884, with the largest shareholder holding 27.34% of the shares[17] Audit Information - The company did not conduct an audit for the Q3 2023 report[33]
拓新药业(301089) - 2023 Q3 - 季度财报